Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 11, 2014 NEW YORK, March 11, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register -- Hospira Inc. Analyst Notes On March 4, 2014, Hospira Inc. (Hospira) announced the appointment of David J. Endicott as President, Hospira Medical Devices, with effect from March 10, 2014. According to Hospira, in this role, Endicott will be responsible for establishing a fully integrated device organization - leading the commercial, research and development, manufacturing and related support functions to continue to advance the Company's product pipeline, execute its device strategy and ultimately drive global growth. F. Michael Ball, CEO of Hospira, commented, "David is an accomplished global leader with more than 25 years of industry experience - 15+ of those where I had the privilege of working with him directly and had an opportunity to see firsthand his proven ability to define, implement and manage sustainable process, organizational and cultural change. With his impressive track record in delivering strong results across all business functions, we're confident David will successfully lead our dual imperatives to execute our device strategy and drive global growth." The full analyst notes on Hospira Inc. are available to download free of charge at: http://www.AnalystsReview.com/03112014/HSP/report.pdf -- Karyopharm Therapeutics, Inc. Analyst Notes On March 5, 2014, Karyopharm Therapeutics, Inc. (Karyopharm) released its full-year 2013 results and provided an update on its clinical development plans. Karyopharm registered revenues of $0.4 million, down 39.0% YoY. The Company posted an annual net loss of $33.9 million, compared to a net loss of $15.9 million in full-year 2012. Diluted net loss came in at $5.59 per share, compared to diluted net loss of $8.95 per share in full-year 2012. Michael Kauffman, Karyopharm CEO, said, "2013 was has been a very important year for Karyopharm, highlighted by robust clinical development activity focused on our novel, first in class, orally active selective inhibitors of nuclear export compounds, also called SINEs." Commenting on its future plans, Kauffman said, "We have moved rapidly from discovery to the clinic. In 2014, we plan to initiate three registration-directed trials in hematological indications and to continue to broaden our solid tumor development activity. This foundation positions us to continue our broad-based development plan to assess the breadth of this novel anti-cancer mechanism." The full analyst notes on Karyopharm Therapeutics, Inc. are available to download free of charge at: http://www.AnalystsReview.com/03112014/KPTI/report.pdf -- Revance Therapeutics, Inc. Analyst Notes On March 5, 2014, Revance Therapeutics, Inc. (Revance) announced the appointment of Angus C. Russell as Chairman of the Board, effective immediately. Commenting on this, Dan Browne, President and CEO of Revance, said, "Angus' impressive track record in the global biopharmaceutical industry will bring significant value to Revance and its Board of Directors." Browne added, "With his extensive experience growing companies commercially, I am thrilled to have him as a partner as we continue to execute and build our business." The full analyst notes on Revance Therapeutics, Inc. are available to download free of charge at: http://www.AnalystsReview.com/03112014/RVNC/report.pdf -- Pluristem Therapeutics, Inc. Analyst Notes On March 6, 2014, Pluristem Therapeutics, Inc. (Pluristem) announced that the US Food and Drug Administration (FDA) has reviewed the Company's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the manufacturing of these products in its new commercial-scale cell manufacturing facility - which has the ability to efficiently produce approximately150,000 doses of PLX cells annually. Zami Aberman, Chairman and CEO of Pluristem, stated, "Knowing that the 'Process is the Product' in cell therapy, we have established our leadership position in the industry by focusing on our 3D commercial scale cell manufacturing processes. To be a successful company in the industry, we believe it is imperative to possess and control the manufacturing processes we have developed at Pluristem. We believe this FDA approval, combined with the approval given by the Paul-Ehrlich-Institute (PEI) of Germany announced on January 23, 2014, is an indication that these regulatory bodies see our proprietary 3D manufacturing process as a valid and sustainable commercial scale solution for potential cell therapies." The full analyst notes on Pluristem Therapeutics, Inc. are available to download free of charge at: http://www.AnalystsReview.com/03112014/PSTI/report.pdf -- Sunesis Pharmaceuticals, Inc. Analyst Notes On March 6, 2014, Sunesis Pharmaceuticals, Inc. (Sunesis) released its Q4 2013 and full year 2013 results. During the quarter, Sunesis registered total revenues of $2.0 million, flat as compared to Q4 2012, while full-year 2013 reported total revenues stood at $8.0 million, up 111.9% YoY. The Company posted quarterly net loss of $7.2 million, compared to net loss of $4.1 million in Q4 2012, and annual net loss of $34.6 million, compared to net loss of $44.0 million in full year 2012. Further, Sunesis reported quarterly diluted net loss of $0.15 per share, compared to diluted net loss of $0.20 per share in Q4 2012, and annual diluted net loss of $0.66 per share, compared to diluted net loss of $0.91 per share in full year 2012. The full analyst notes on Sunesis Pharmaceuticals, Inc. are available to download free of charge at: http://www.AnalystsReview.com/03112014/SNSS/report.pdf -- About Analysts Review We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities. -- ============= EDITOR NOTES: oThis is not company news. We are an independent source and our views do not reflect the companies mentioned. oInformation in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. oThis information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. oIf you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@AnalystsReview.com. oFor any urgent concerns or inquiries, please contact us at compliance@AnalystsReview.com. oAre you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@AnalystsReview.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts Review Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
Press spacebar to pause and continue. Press esc to stop.